Dikarbamin

General characteristics. Structure:

Active agent: имидазолилэтанамид pentandiovy acid (Vitaglutam) of 100 mg, (in terms of 100% substance)
 
Excipients: lactose (sugar milk); potato starch; silicon dioxide colloid (aerosil); talc; magnesium stearate; stearic acid.

Pharmacological properties:

Pharmacodynamics. Accelerates a differentiation and functional maturing of neutrophils.
The Gematoprotektorny effect of Dikarbamin at myelosuppressive chemotherapy is caused by acceleration of maturing of predecessors of neutrocytes on a mode of formation of specific granules. As a result — there is a reduction of degree and frequency of a toxic neutropenia of the III-IV degree. The therapeutic effect of Dikarbamin is shown at daily inclusion within 21–28 days during the period between the planned chemotherapy courses.
Causes reduction of the frequency of emergence limiting leucio-and neutropenias, allows to carry out treatment to the planned terms without decrease in doses of tsitostatik and risk of hematologic complications.

Pharmacokinetics. Drug in 10 min. is defined in a blood plasma. Cmax is reached in 30 min. and during 2 h decreases. Drug is quickly and evenly distributed on internals. The considerable share of the administered drug is removed with urine.

Indications to use:

Gematoprotektion at the patients receiving chemotherapy cytotoxic means concerning malignant new growths.

Route of administration and doses:

Inside. Daily in a single dose of 100 mg (1 tab.) in 5 days prior to the beginning of the first course of chemotherapy and further — throughout the entire period of chemotherapy.

Features of use:

There are no data.

Side effects:

Allergic reactions: skin rash (seldom).

Interaction with other medicines:

Dikarbamin strengthens antineoplastic action of tsitostatik. Drug influence Dikarbamin on specific activity of cyclophosphamide and its combinations with platinum drugs is investigated (Cisplatinum and karboplatiny). The research conducted on mice showed that Dikarbamin's use together with cytostatics leads to increase and prolongation of antineoplastic effect. Besides, Dikarbamin reduces toxic effect of cyclophosphamide and its combinations with platinum drugs (Cisplatinum and karboplatiny) at Dikarbamin's introduction within 5 days to antineoplastic drugs and further as before dosing, development of a deep cytopenia prevents and accelerates hemopoiesis recovery processes.

Contraindications:

Hypersensitivity to Dikarbamin or other components of drug.

Use at pregnancy and feeding by a breast
It is contraindicated at pregnancy. For the period of treatment it is necessary to stop breastfeeding.

Overdose:

The specific antidote to Dikarbamin is not known.

Storage conditions:

In the dry, protected from light place, at a temperature not above 25 °C.
To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

7 - cardboard strip packagings (3) - packs cardboard.